Trial Profile
A Phase 2, Multicenter, Placebo-controlled, Double-blind, Randomized, Parallel-group Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 09 Sep 2020 Primary endpoint (Change From Baseline in Daily Urine Volume) has been met as per results published in the Nephrology Dialysis Transplantation
- 09 Sep 2020 Results published in the Nephrology Dialysis Transplantation
- 27 Dec 2016 Status changed from active, no longer recruiting to completed.